Home Blog Page 2385

iBoozee Launches Asia’s First Smart Robotic Juice Machines in Singapore

By
Advertorial Desk
-

Award-winning innovation set to deploy 500 units islandwide; transformation of healthy juice-on-the-go for millions

SINGAPORE – Media OutReach Newswire – 18 September 2025 – iBoozee, an ASEAN Award-winning innovator in the food and beverage technology sector, today marked a new milestone in its expansion with the unveiling of its Smart Robotic Mixed Fruit Juice and Apple Machines in Singapore. Building on over a year in the market, this launch reaffirms iBoozee’s leadership in redefining healthy, on-the-go choices through freshness, innovation, and lifestyle convenience.

iBoozee, the ASEAN award-winning innovator, redefines freshness with its breakthrough Automated Dual Fruit Juice Machine.
iBoozee, the ASEAN award-winning innovator, redefines freshness with its breakthrough Automated Dual Fruit Juice Machine.

The iBoozee vending machines are the first in Asia to feature Dual Fruit Dispensing Technology, allowing customers the experience of enjoying either pure apple juice, orange juice, or a customised mix—all freshly pressed on demand. Each serving contains the equivalent of 3-4 of an apple or orange, with no added sugar, water, or preservatives, making this an excellent lifestyle choice for anyone living in a city with a hectic pace and who yet want the best and freshest to stay fit and sharp.

Healthy Convenience, Powered by Smart Tech
More than just machines, iBoozee deliver:

  • Robotic Processing Technology: Fruits are washed, cut, squeezed, and served in real time, with a transparent process customers can watch.
  • Smart IoT Monitoring: Operators receive live data on sales, inventory, and machine performance, ensuring consistent quality and uptime.
  • Cashless Transactions: Fully integrated with PayNow, NETS, cards, and e- wallets for a seamless, hygienic experience.
  • Food Safety & Hygiene: Self-cleaning cycles and airtight storage ensure all its fruits are kept fresh, in tip-top condition and safe for consumption.

Says Mr Deric Yeo, Group Chief Operating Officer of iBoozee: “We believe that true wellness shouldn’t be complicated or costly. In the midst of a hectic day, a healthy choice should be the easiest one to make. Hence, we created our Smart Robotic Mixed Fruit and Apple Juice: to offer a drink that is not only refreshing and affordable but genuinely better for you. For the student sprinting to class, the professional powering through an afternoon, or the parent needing a nourishing moment—this is for you. iBoozee is our commitment to making wellness convenient, accessible, and within everyone’s reach.”

With an ambitious goal of deploying 500 units across Singapore by end 2027, iBoozee is truly poised to become the nation’s largest provider of smart robotic juice machines. The initial roll-out of these machines will include high traffic locations to maximise visibility and convenience. Commercial buildings like offices and shopping malls, public transportation hubs and high-impact neighbourhoods like the Central Business District will be the first to enjoy these smart robotic juice machines. iBoozee’s future-ready machines are already present in Malaysia and concrete plans for expansion are in place for key markets like Indonesia and the Philippines.

Opportunities for Entrepreneurs
Beyond healthy living, iBoozee is opening the door to entrepreneurship through licensing opportunities. The model is designed to be accessible for working professionals, aspiring entrepreneurs, and retirees, supported by real-time data analytics that optimise machine placement and performance.

“As Singapore embraces cashless convenience and healthier living, iBoozee is setting a new benchmark for the vending industry,” said Mr Yeo. “We are not just offering juice—we are offering an entrepreneurial lifestyle opportunity, where partners can grow with us in this next wave of smart retail.”

Showcasing at Franchise & Licensing Asia 2025
iBoozee will showcase its latest machines at the Franchise & Licensing Asia Expo (Marina Bay Sands, 18–20 September 2025), inviting franchise partners and investors to join its vision of making healthier choices available 24/7 across Singapore.

Hashtag: #iBoozee #JuiceMachines

The issuer is solely responsible for the content of this announcement.

About iBoozee

iBoozee is a proud Singapore brand and ASEAN Award-winning innovator in the F&B vending sector, pioneering Asia’s first Smart Robotic Dual Fresh Fruit Juice Machine. By merging cutting-edge technology with health-conscious living, iBoozee delivers fresh, hygienic, and convenient juice solutions while empowering entrepreneurs through scalable licensing opportunities.

H2G Green Limited’s GasHub Commissions Major LNG Facility for Leading F&B Manufacturer

By
Advertorial Desk
-

The GasHub-led conversion from diesel to LNG is estimated to decrease the carbon footprint of the production facility by approximately 30%.

SINGAPORE, Sept. 18, 2025 /PRNewswire/ — H2G Green Limited (SGX:5AI) (“H2G” or the “Company“, together with its subsidiaries, collectively the “Group“), one of the leading sustainable energy solutions providers, and its subsidiary GasHubUnited Utility Private Limited (“GasHub“) today announced the completion and commissioning of one of its largest liquefied natural gas (“LNG“) facilities to date, built for a leading food and beverage (“F&B“) manufacturer in Singapore.


GasHub has led the F&B manufacturer in transitioning its operations from diesel to LNG, retrofitting its current production site in Singapore. GasHub completed the retrofitting recently and made its first LNG delivery to prepare the facility to begin using LNG.

Designed, constructed, and commissioned by GasHub, the new LNG facility will substantially support the F&B manufacturer’s thermal energy needs for manufacturing consumer beverage products for regional markets.

“Industrial facilities represent a significant opportunity for Singapore to reduce emissions and strengthen energy security through switching to LNG,” said Bentinck Ng, CEO of GasHub. “Our partnership with this leading F&B manufacturer showcases how LNG can deliver various benefits. By replacing diesel, companies can significantly reduce carbon footprints and maintenance costs while benefiting from cleaner, more efficient operations. At the same time, this project highlights the unique, homegrown engineering expertise GasHub brings to Singapore’s industrial energy sector—a space often overlooked compared to power generation. If more companies follow, together we can accelerate progress toward a greener, more energy-secure Singapore.”

Driving efficiency and sustainability

The facility’s conversion to LNG will achieve significant benefits:

  • Reduced emissions: The switch is estimated to lower the carbon footprint of the manufacturer’s production facility by approximately 30%.
  • Cleaner operations: Unlike diesel, LNG combustion leaves no carbon residue, reducing maintenance requirements and improving boiler efficiency.
  • Improved stability in energy cost: LNG provides an energy source with greater cost stability and long-term efficiency, helping to increase financial stability and predictability.
  • Improved workplace environment: LNG combustion eliminates odour and potential contamination associated with diesel use.

With this transition, this F&B manufacturer is now one of the largest LNG users GasHub supplies to date.

Trusted by industry leaders

In addition to improving sustainability, GasHub was selected for the project due to its proven engineering expertise in designing, building, and maintaining LNG infrastructure for industrial clients.

About H2G Green Limited

H2G focuses on delivering sustainable energy solutions through its two subsidiaries: GasHub for LNG and Green Energy Investment Holding Private Limited for hydrogen, biochar, and other high-value, sustainable materials. In Singapore, the Company is working towards solving the energy trilemma — advancing cost competitiveness of sustainable energies, expanding energy security, and transitioning to net zero. Beyond Singapore, the Company is powering Southeast Asia’s transition towards cleaner, sustainable energy solutions. H2G stands out for deep engineering, energy, and sustainability expertise and an unwavering commitment to safety.

For more information, please visit: https://h2g.green.

NAVER CEO Choi Soo-yeon Appointed to UN Global Compact Board of Directors, Strengthening International Partnerships for “AI Governance”

By
Advertorial Desk
-

– CEO Choi recognized for her leadership in global dialogues and cooperation to advance safe AI development and establish a digital ecosystem

– Sanda Ojiambo, CEO and Executive Director of the UN Global Compact, said, “CEO Choi Soo-yeon’s global leadership and deep expertise will be a great asset in achieving the UN Global Compact ‘s goals.”

SEONGNAM, South Korea, Sept. 18, 2025 /PRNewswire/ — NAVER Corporation (CEO Choi Soo-yeon) announced on September 18 (local time) that CEO Choi has been officially appointed as a new member of the Board of Directors of the United Nations Global Compact. This appointment recognizes her contribution in taking a leading role in international discussions to establish a safe AI ecosystem. As a board member, CEO Choi will serve a three-year term, actively participating in regular board meetings and key UN Global Compact activities.

Choi Soo-yeon, CEO of NAVER Corporation
Choi Soo-yeon, CEO of NAVER Corporation

The UN Global Compact is the world’s largest voluntary corporate citizenship initiative, with more than 25,000 companies and organizations across 167 countries. Established in July 2000, it presents ten principles in the four key areas of human rights, labor, environment, and anti-corruption, supporting companies in practicing responsible management for sustainable growth. In Korea, 360 companies in the private sector are participating in the UN Global Compact.

The UN Global Compact recognized CEO Choi’s leadership in spearheading international cooperation and dialogue on “AI governance,” aimed at establishing ethical and responsible principles throughout the full cycle of AI technology development. At the AI Action Summit held in Paris in February this year, she joined global leaders to discuss the future direction of AI development and outlined NAVER’s vision for securing diversity within the digital ecosystem through AI. In June 2024, NAVER introduced the AI Safety Framework (ASF), a comprehensive approach to identifying and managing potential risks across all stages of AI systems.  

The UN Global Compact also commended CEO Choi for establishing NAVER Ventures in Silicon Valley, where she has built a collaborative ecosystem by identifying and supporting promising startups across diverse nationalities and sectors. In addition, through the launch of NAVER Impact in 2024, CEO Choi has consistently emphasized sustainable growth in partnership with local communities, SMEs, and startups.

Sanda Ojiambo, CEO & Executive Director of the UN Global Compact, announced, “Choi Soo-yeon brings deep expertise on how digital companies can create value and scale globally while upholding principles on responsible and sustainable business. We look forward to her participation on our Board as we mobilize business to deliver the Sustainable Development Goals (SDGs).”

Lee Dong-Kurn, President of the UN Global Compact Network Korea, stated, “We are delighted that CEO Choi Soo-yeon has been appointed as a UN Global Compact board member, the first Korean in 17 years. We look forward to NAVER continuing to lead the establishment of a sustainable management ecosystem on the global stage and to playing an active role as a global leader through ongoing collaboration with the UN Global Compact.”

Following her appointment, CEO Choi will attend the upcoming UN Global Compact Board meeting at the UN Headquarters in New York on September 20 (U.S. local time). As a newly appointed board member, she is expected to actively participate in transnational discussions on establishing ethical AI governance on the global stage.

About NAVER

Founded in 1999, NAVER is Korea’s largest Internet company and one of the world’s top tech companies. Leading cutting-edge technologies, NAVER operates No.1 search engine in Korea and holds various business portfolios encompassing commerce, fintech, cloud, AI and robotics.

NAVER recorded sales of KRW 10.74 trillion (USD 7.5 billion) in 2024. TEAM NAVER continues to enhance its business portfolio and expand its global presence across Japan, North America, and Europe, while pursuing innovation through continuous research and development in future technologies.

To learn more, visit www.navercorp.com/en 

Nuix Wins Multiyear Contract with German Tax Authority to Strengthen Investigative and Regulatory Capabilities

By
Advertorial Desk
-

SYDNEY, Sept. 18, 2025 /PRNewswire/ — Nuix (‘the Company’, ASX: NXL) today announces it has won a multiyear contract to supply forensic analysis software to the tax authority of German state Rhineland-Palatinate (Landesamt für Steuern Rheinland-Pfalz).

Nuix Neo automates workflows, ingesting data from over 1,000 file types at scale. Using responsible AI, advanced automation, and deep link-analysis, the software enables investigators to uncover the truth in vast, complex datasets and collaborate in real time. Nuix delivers consistent, auditable, and defensible results, bringing critical evidence to the surface.

Globally, Nuix supports tax authorities, integrity agencies, and other regulators in centralising and analysing large datasets to help investigators detect financial irregularities, strengthen tax compliance, and enhance the efficiency of investigative processes.

Jonathan Rubinsztein, CEO of Nuix, said: “This partnership underscores why nearly 100 regulators worldwide trust Nuix for their most complex investigations. As the go-to technology for regulators worldwide, we’re proud to support the State Tax Authority for Rhineland-Palatinate in driving regulatory excellence and uncovering truth.

“Our partnership with the State Tax Authority for Rhineland-Palatinate reflects a shared vision for innovation and integrity in regulatory work. We’re proud to help them achieve their goals.”

Stefan Dörn, Project Manager in the Tax Administration of Rhineland- at Landesamt für Steuern Rheinland-Pfalz, said: “Following a Europe-wide tender process, we chose Nuix which offered the best solution for our organization. Its technology can help streamline and accelerate our audits and investigations to more efficiency.”

Contact:
Alice Ridgway 
alice.ridgway@nuix.com

NYSE Content Advisory: Annual International Day Slate Announced

By
Advertorial Desk
-

NEW YORK, Sept. 18, 2025 /PRNewswire/ — The New York Stock Exchange will hold the 2nd annual NYSE International Day, on October 23, 2025, celebrating global business excellence and fostering cross-border innovation and investment. The event is designed to bring together C-suite executives of international innovators, PE/VC investors, and the NYSE listed community for a half-day of insightful discussions, networking, and product showcases, followed by a networking reception on the Trading Floor.

NYSE Content Advisory: Annual International Day Slate Announced
NYSE Content Advisory: Annual International Day Slate Announced

International companies from regions including Canada, UK/Europe, MEA, APAC and Latin America will showcase products and innovations during networking breaks. Scheduled sessions will include discussions on the future of fintech, scaling businesses beyond borders globally, future mobility innovations, exit strategies balancing M&A and IPOs, and bridging private and public markets for late-stage companies.

Announced speakers include:

  • Jim Cramer, CNBC host, who will deliver the Opening Keynote interview alongside NYSE President Lynn Martin
  • Scarlett Sieber, Chief Strategy & Growth Officer, Money20/20
  • Frederik Thomasen, Head of Equity Capital Markets, Norges Bank Investment Management (NBIM)
  • Anu Aiyengar, Managing Director, Global Head of Advisory and Mergers & Acquisitions, J.P. Morgan
  • Masaki (Mory) Morimoto, President, The House of Suntory
  • Wen Han, Founder, Chairman & CEO, Windrose Technology

Click here to REGISTER and learn more about NYSE International Day

 

Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025

By
Advertorial Desk
-

–Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo.

–Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) in the denifanstat (ASC40) group were comparable to placebo: 58.6% versus 56.3%. The majority of TEAEs were mild (Grade 1) or moderate (Grade 2).

–Pre-New Drug Application (NDA) consultation of denifanstat (ASC40) with the China National Medical Products Administration (NMPA) is ongoing and feedback received from NMPA so far is encouraging. Ascletis plans to submit an NDA for denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris to NMPA after completing its pre-NDA consultation.

HONG KONG, Sept. 18, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today that the oral presentation of the Phase III study results of denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris (NCT06192264) was presented in the Late Breaking News sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France on September 17, 2025.

Details of the Oral Presentation

Title: First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase Ⅲ Randomised Placebo Controlled Trial

Presenter: Dr. Leihong (Flora) XIANG, M.D and Ph.D., Principal Investigator of denifanstat (ASC40) Phase III study, Department of Dermatology, Huashan Hospital, Fudan University

The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat (ASC40) once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat (ASC40) oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat (ASC40) and placebo arms.

Primary endpoints included the percent treatment success, defined as an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12, the percent reductions from baseline to week 12 in total lesion count (TLC), and the percent reduction from baseline to week 12 in inflammatory lesion count (ILC).

After 4-week treatment, the denifanstat (ASC40) group already showed statistically significant improvements (p<0.05) over placebo in multiple efficacy endpoints, including treatment success, TLC, ILC, and non-inflammatory lesion count (NILC).

After 12-week treatment, denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints. Table 1 summarizes efficacy results from the Phase III study versus placebo (intent-to-treat, ITT analysis). 

Table 1. Efficacy results from the Phase III study versus placebo (intent-to-treat, ITT analysis)

Efficacy endpoints (1)

50 mg
denifanstat (ASC40), oral,
once daily

(n=240)

Placebo,
oral, once
daily

(n=240)

Placebo

adjusted

 

P value

 

Primary endpoints

Percent treatment

success (2)

33.17

14.58

18.59

<0.0001

Percent reduction from
baseline in TLC

57.38

35.42

21.96

<0.0001

Percent reduction from
baseline in ILC

63.45

43.21

20.24

<0.0001

Key secondary endpoint

Percent reduction from
baseline in NILC

51.85

28.94

22.91

<0.0001

Secondary endpoints

Absolute reduction from
baseline in TLC

58.25

36.17

22.08

<0.0001

Absolute reduction from
baseline in ILC

26.56

18.42

8.14

<0.0001

Notes:

(1)  All efficacy endpoints are least square means.

(2)  Treatment success is defined as an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12.

(3) TLC: total lesion count; ILC: inflammatory lesion count; NILC: non-inflammatory lesion count.

Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat (ASC40) and placebo: 58.6% versus 56.3%. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat (ASC40) -treated patients versus 2.9% in the placebo group; 5.9% xerophthalmia in denifanstat (ASC40) -treated patients versus 3.8% in the placebo group). The majority of TEAEs were mild (Grade 1) or moderate (Grade 2). All denifanstat (ASC40) -related TEAEs were mild (Grade 1) or moderate (Grade 2). There were no denifanstat (ASC40) -related Grade 3 or 4 TEAEs and no denifanstat (ASC40) -related serious AEs (SAEs). No deaths were reported. No denifanstat (ASC40) -related permanent treatment discontinuations or withdrawals were observed.

Detailed data presented at the EADV Congress 2025 can be found at Ascletis’ website (link).

“Denifanstat (ASC40) is an innovative and potentially meaningful advancement for the treatment of acne and we’re very pleased that we have presented these results to the dermatology community at this year’s EADV Congress,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “Denifanstat (ASC40) has a new mechanism of action for acne treatment and demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary and secondary endpoints in the Phase III study, as well as a favorable safety and tolerability profile.”

Pre-New Drug Application (NDA) consultation of denifanstat (ASC40) with the China National Medical Products Administration (NMPA) is ongoing and feedback received from NMPA so far is encouraging. Ascletis plans to submit an NDA for denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris to NMPA after completing its pre-NDA consultation.

Ascletis licensed denifanstat (ASC40) from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

To learn more about Ascletis, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

MagicRNA’s First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.

By
Advertorial Desk
-
  • First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients.
  • Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in complete depletion of circulating B cells and up to 20-points reduction in patient’s SLEDAI scores within three months.
  • Favourable safety profile with no neurotoxic effects or other severe adverse events, no clinically significant elevation of liver enzymes was observed during or after treatment in any of the 5 patients.

SHENZHEN, China, Sept. 18, 2025 /PRNewswire/ — MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world’s first clinical data of an mRNA-lipid nanoparticle (mRNA-LNP) based in vivo CAR T candidate, HN2301, in The New England Journal of Medicine. The study, titled “In vivo CD19-CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus”, represents the first-ever demonstration of in vivo CAR T generation and activity in SLE patients.

“This study is an important milestone for the entire field of cell therapy,” said Prof. Georg Schett, pioneer in the use of CD19 CAR T cell therapy in SLE and achieved a revolutionary breakthrough. “For the first time, we see functional CAR T cells generated directly in patients’ body, achieving rapid B-cell clearance and clinical improvement of autoimmune disease. These findings, together with the favorable safety profile, pave the way for a new era of immunotherapy.”

The clinical trial enrolled five patients with long-standing, treatment-refractory SLE, four of whom also had lupus nephritis. Built on MagicRNA’s EnC-LNP delivery platform technology, HN2301 was administered intravenously without prior lymphodepletion to deliver CAR-encoding mRNA to CD8+ T cells, reprogramming them into CD19-targeted CAR T cells in vivo.

“This study marks the first clinical proof-of-concept of the cell targeted-LNP based in vivo CAR T-cell in autoimmune disease, validating its therapeutic potential in patients,” said Dr. Gavin Zha, CEO of MagicRNA. “By achieving deep B-cell depletion, in vivo CAR T technology offers a new level of disease control that potentially goes beyond what has been achieved with conventional approaches such as monoclonal antibodies and T-cell engagers. At the same time, it overcomes the major limitations of ex vivo CAR T therapies, including complex manufacturing, long preparation times, high costs, and the requirement for lymphodepletion. Our platform has the potential to make transformative cell therapies broadly accessible and scalable for patients.”

At a minimal dose (2 mg per infusion), single or repeated administration of HN2301 induced CAR T-cells generation and B-cell reduction. At a bit higher dose (4 mg per infusion) up to 60% of CD8+ CAR+T-cells were reprogrammed within six hours, leading to complete depletion of circulating B cells, which persisted for 7-10 days. Consistent with B-cell depletion, anti-nucleosome and anti-dsDNA antibodies significantly decreased, and low complement levels in some patients normalized at the last visit. In addition, Disease Activity Index (SLEDAI-2000) scores significantly decreased by as much as 20 points in all 5 patients 3 months after the infusion of HN2301. The treatment was generally well tolerated, no patients experienced grade ≥3 CRS, and no neurotoxic effects or other severe adverse events were observed during or after treatment.

Based on these encouraging clinical results, MagicRNA will continue the dose-escalation studies to further evaluate HN2301’s ability to achieve immune reset and long-term drug-free remission, with the goal of accelerating clinical development and ultimately bringing this therapy to patients worldwide.

About HN2301
HN2301 is MagicRNA’s lead investigational therapy and the world’s first in vivo CAR T candidate to enter clinical testing in SLE patients. HN2301 encapsulates CD19 CAR-encoding mRNA in a proprietary T-cell-targeted lipid nanoparticle (EnC-LNP), enabling direct reprogramming of patient T cells into functional CAR T cells in vivo. In preclinical studies, including nonhuman primates and mouse models, HN2301 achieved rapid and robust CAR T reprogramming and complete depletion of B cells in blood and tissues. Early first-in-human data demonstrated feasibility, clinical efficacy, and favourable safety profile.

About MagicRNA
MagicRNA Biotechnology, founded in 2021, is a clinical-stage biotech company pioneering next-generation mRNA and lipid nanoparticle (LNP) technologies to expand the reach of RNA-based medicines. The company’s proprietary Engineered Cell-targeted LNP (EnC-LNP) platform enables precise delivery of mRNA into non-antigen presenting cells (non-APC) outside the liver, overcoming a key limitation of conventional liver-targeted LNPs. MagicRNA is establishing itself as a global leader in the field of engineered cell-targeted LNP based therapeutics. In addition to its lead program, HN2301, MagicRNA is advancing a pipeline of in vivo cell reprogramming therapeutics and cell-targeted LNP based medicines across immune-related diseases.

About SLE
Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease affecting an estimated 3.4 million people globally, with a prevalence of approximately 44 per 100,000 individuals. The disease disproportionately affects women of childbearing age and is characterized by immune-mediated inflammation and tissue damage across multiple organs, with lupus nephritis being one of the most severe and life-threatening manifestations. Traditional standard treatments for SLE, including corticosteroids, immunosuppressants, and biologics, can help control symptoms, but many patients continue to experience recurrent relapses driving progressive multiple-tissue damage and life-threatening complications. B cells play a pivotal role in the pathogenesis of SLE by producing autoantibodies, and the “B cell reset”-induced drug-free remission of SLE has been extensively validated by clinical reports.

MagicRNA Contacts
info@magicrna.com
www.magicrna.com

Media:
Shirley.lu@bfcgroup.biz
Wendy.li@bfcgroup.biz 

UN Secretary-General appoints CEO of Naver to the UN Global Compact Board

By
Advertorial Desk
-

NEW YORK, Sept. 18, 2025 /PRNewswire/ — UN Secretary-General António Guterres, who serves as Board Chair of the UN Global Compact, today welcomed Choi Soo-yeon, CEO of Naver, to the UN Global Compact Advisory Board. The UN Global Compact is the world’s largest corporate sustainability initiative.

Choi Soo-yeon became the CEO of Naver, South Korea’s biggest internet company, in 2022. She is its second female CEO and its youngest non-founder CEO. A corporate/M&A lawyer by training at Yulchon and an LL.M. graduate of Harvard Law School (2018), she rejoined NAVER in 2019 to lead global business initiatives before taking the helm. As CEO, she is driving NAVER’s AI-first global expansion—rolling out “on-service AI” across core products and launching NAVER Ventures in the United States to back high-potential startups and deepen international partnerships. Her governance, responsible-tech and cross-border operating experience aligns closely with the mission of the UN Global Compact; Naver has been an active participant of the UN Global Compact since 2014.

“Choi Soo-yeon brings deep expertise on how digital companies can create value and scale globally while upholding principles on responsible and sustainable business. We look forward to her participation on our Board as we mobilize business to deliver the Sustainable Development Goals,” said Sanda Ojiambo, CEO and Executive Director of the UN Global Compact. 

Lee Dong-Kurn, President of the UN Global Compact Network Korea stated “We are delighted that CEO Choi Soo-yeon has been appointed as a UN Global Compact board member, the first Korean in 17 years. We look forward to NAVER continuing to lead the establishment of a sustainable management ecosystem on the global stage and to playing an active role as a global leader through ongoing collaboration with the UN Global Compact.”

As a special initiative of the UN Secretary-General, the UN Global Compact is a call to companies everywhere to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. The UN Global Compact challenges businesses to take concrete actions to accelerate progress on the Sustainable Development Goals (SDGs).

The UN Global Compact Board plays an important role in shaping the strategy and policy of the initiative, which acts as the UN flagship for responsible business action. Designed as a multi-stakeholder body, the Board provides ongoing strategic and policy advice for the initiative. Board members are considered champions who are willing and able to advance the mission of the UN Global Compact. They act in a personal, honorary and unpaid capacity.

For the current list of board members please refer to: www.unglobalcompact.org/about/governance/board/members

Notes to Editors

About the UN Global Compact
The ambition of the UN Global Compact is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the SDGs through accountable companies and ecosystems that enable change. With more than 20,000 participating companies, 5 Regional Hubs, 64 Country Networks covering 85 countries and 9 Country Managers establishing Networks in 16 other countries, the UN Global Compact is the world’s largest corporate sustainability initiative — one Global Compact uniting business for a better world. For more information, follow @globalcompact on social media and visit our website at unglobalcompact.org.

1...2,3842,3852,386...6,464Page 2,385 of 6,464